ATOS - הערכת שווי הפעילות בספרים atossatherapeutics.com

Atossa Therapeutics (ATOS) leverages the success of (Z)-endoxifen in breast tumor therapy and anticipates deals with major pharmaceutical behemoths. This chart on the GURU.Markets platform, where the metric stands at 0.03, visualizes the asset's price action. The business focuses on developing preventive treatments for early-stage cancer, targeting large-scale demand. Development is conducted in collaboration with specialized medical centers to refine endocrine treatment methods for women.

To assess the stability of Atossa Therapeutics (ATOS), it is essential to analyze the real value of its net assets. The history of book capitalization changes demonstrates the gap between the market price and actual capital net of liabilities. This indicator reveals the risk of inflated quotes during periods of declining liquidity. For the biotech sector, this metric reflects the value of intellectual property and clinical trial expenditures. A high level of capital confirms the financial foundation required for the development of anti-cancer drugs.